Ipamorelin side effects: what the literature reports

A clean GHRP profile in the literature is not the same as no profile.

TL;DR

• In animal studies, ipamorelin was more selective than older GHRPs (in plain English: small molecules that signal the pituitary to release growth hormone).
• The most common reported effects are injection-site reactions, transient flushing, mild headache, and temporary hunger.
• Compounded ipamorelin is not FDA-approved, and long-term human safety data are limited.

What it is

Ipamorelin is a synthetic GHRP (growth hormone-releasing peptide) developed in the late 1990s. What drew researchers' interest is what it did not do: in animal studies, it triggered a growth hormone pulse without meaningfully raising cortisol or prolactin (Raun et al., Eur J Endocrinol, 1998).

How it works

Picture a doorbell with five buttons. Older GHRPs press the growth hormone button — and accidentally lean on the cortisol and prolactin buttons too. In animal studies, ipamorelin pressed just the one button. A study in healthy men found a single, short growth hormone release at every dose tested (Gobburu et al., Clin Pharmacokinet, 1999).

Who asks about it

People usually ask about side effects after reading marketing copy that calls ipamorelin "side-effect free." It is not. In animal studies it was cleaner, in the sense that the unwanted bell presses were quieter. That is not the same as zero risk, and it has not been confirmed in long-term human studies.

What the research says

Reported effects include injection-site irritation, transient flushing, lightheadedness, and a temporary increase in appetite (consistent with growth hormone secretagogue activity). Headache and mild fatigue have been reported. The cortisol rise seen with GHRP-6 and GHRP-2 was absent with ipamorelin in animal studies, even at high doses (Raun et al., 1998). Long-term human data is limited.

Open safety questions

Growth hormone activity can shift insulin sensitivity, and growth hormone signaling raises concern in active cancer and untreated retinopathy. Long-term human safety data on ipamorelin are limited. Compounded ipamorelin is not FDA-approved.

The Halftime POV

A compound being "clean" in animal studies is not a green light. It is a starting point for research, not proof of safety in people. Short human studies cannot show long-term risk, and long-term human data on ipamorelin are scarce.

Related reading:

• Ipamorelin: what this GHRP peptide is
• Ipamorelin research: published evidence reviewed
• CJC-1295 and ipamorelin: the research on the pair

FAQ

Q: What are the most common ipamorelin side effects? A: Published trials and case reports describe injection-site reactions, mild headache, transient flushing, lightheadedness, and a temporary increase in hunger. Most reactions are short-lived. In animal studies, its effect on cortisol was minimal compared with older GHRPs.

Q: Does ipamorelin raise cortisol? A: Compared with earlier GHRPs (GHRP-2 and GHRP-6), ipamorelin showed little to no effect on cortisol in animal studies. That finding has not been confirmed in long-term human studies.

Q: Is ipamorelin FDA-approved? A: No. Ipamorelin is not FDA-approved as a finished drug product. Compounded ipamorelin is not FDA-approved. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved.

Sources

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
• Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin. Clinical Pharmacokinetics, 1999.

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.